These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2997488)

  • 1. Inhibitors of crystal growth of hydroxyapatite: a constant composition approach.
    Wilson JW; Werness PG; Smith LH
    J Urol; 1985 Dec; 134(6):1255-8. PubMed ID: 2997488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of urine, pyrophosphate, citrate, magnesium and glycosaminoglycans on the growth and aggregation of calcium oxalate crystals in vitro.
    Ryall RL; Harnett RM; Marshall VR
    Clin Chim Acta; 1981 May; 112(3):349-56. PubMed ID: 6263523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergism between the brushite and hydroxyapatite urinary crystallization inhibitors.
    Costa-Bauzá A; Barceló C; Perelló J; Grases F
    Int Urol Nephrol; 2002; 34(4):447-51. PubMed ID: 14577482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of hydroxyapatite and pyrophosphate on the formation product of calcium oxalate at different pHs.
    Baumann JM; Ackermann D; Affolter B
    Urol Res; 1989; 17(3):153-5. PubMed ID: 2546312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of calcium oxalate monohydrate crystallization kinetics in vitro.
    Kok DJ; Papapoulos SE; Blomen LJ; Bijvoet OL
    Kidney Int; 1988 Sep; 34(3):346-50. PubMed ID: 2459439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modifiers of calcium oxalate crystallization found in urine. I. Studies with a continuous crystallizer using an artificial urine.
    Robertson WG; Scurr DS
    J Urol; 1986 Jun; 135(6):1322-6. PubMed ID: 2423714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urolithiasis inhibitors and calculus nucleation.
    Grases F; Gil JJ; Conte A
    Urol Res; 1989; 17(3):163-6. PubMed ID: 2546313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting calcium oxalate dihydrate fragmented calculi regrowth.
    Costa-Bauzá A; Perelló J; Isern B; Sanchis P; Grases F
    BMC Urol; 2006 Jul; 6():16. PubMed ID: 16822299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Mixtures of Magnesium, Citrate and Phytate as Calcium Oxalate Crystallization Inhibitors in Urine.
    Grases F; Rodriguez A; Costa-Bauza A
    J Urol; 2015 Sep; 194(3):812-9. PubMed ID: 25818031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of hypocitraturia and hypopyrophosphaturia in recurrent calcium stone formers: as isolated defects or associated with other metabolic abnormalities.
    Laminski NA; Meyers AM; Sonnekus MI; Smyth AE
    Nephron; 1990; 56(4):379-86. PubMed ID: 1964200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scanning electron microscopic study of the effect of citrate and pyrophosphate on calcium oxalate crystal morphology.
    Shirane Y; Kagawa S
    J Urol; 1993 Dec; 150(6):1980-3. PubMed ID: 8230549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypocitraturia in calcium nephrolithiasis.
    Rudman D; Kutner MH; Redd SC; Waters WC; Gerron GG; Bleier J
    J Clin Endocrinol Metab; 1982 Dec; 55(6):1052-7. PubMed ID: 7130336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of inhibitor deficiency in urolithiasis. I. Rationale of urinary magnesium, citrate, pyrophosphate and glycosaminoglycan determinations.
    Akinci M; Esen T; Koçak T; Ozsoy C; Tellaloğlu S
    Eur Urol; 1991; 19(3):240-3. PubMed ID: 1649759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of phytate and pyrophosphate on brushite and hydroxyapatite crystallization. Comparison with the action of other polyphosphates.
    Grases F; Ramis M; Costa-Bauzá A
    Urol Res; 2000 Apr; 28(2):136-40. PubMed ID: 10850638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary crystal growth: effect of inhibitor mixtures.
    Werness PG; Bergert JH; Lee KE
    Clin Sci (Lond); 1981 Oct; 61(4):487-91. PubMed ID: 6169479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artificial simulation of renal stone formation. Influence of some urinary components.
    Grases F; Costa-Bauzá A; March JG; Söhnel O
    Nephron; 1993; 65(1):77-81. PubMed ID: 8413796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adsorption and mineralization effects of citrate and phosphocitrate on hydroxyapatite.
    Johnsson M; Richardson CF; Sallis JD; Nancollas GH
    Calcif Tissue Int; 1991 Aug; 49(2):134-7. PubMed ID: 1655175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrophosphate, phosphate ion interaction: effects on calcium pyrophosphate and calcium hydroxyapatite crystal formation in aqueous solutions.
    Cheng PT; Pritzker KP
    J Rheumatol; 1983 Oct; 10(5):769-77. PubMed ID: 6315937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular modifiers reveal a mechanism of pathological crystal growth inhibition.
    Chung J; Granja I; Taylor MG; Mpourmpakis G; Asplin JR; Rimer JD
    Nature; 2016 Aug; 536(7617):446-50. PubMed ID: 27501150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Citric acid or citrates in urine: which should we focus on in the prevention of calcium oxalate crystals and stones?
    Laube N; Jansen B; Hesse A
    Urol Res; 2002 Oct; 30(5):336-41. PubMed ID: 12389124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.